Overview

Open-Label Extension Study of Kuvan for Autism

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

This is an open-label extension study available only to subjects who completed an earlier double-blind, placebo-controlled study of sapropterin in children with autism.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

The Children's Health Council

Collaborator:

BioMarin Pharmaceutical

Treatments:

Verapamil